



Setting up a biobank: regulatory and ethical considerations

Dr Claire Lewis
Operational Manager
Northern Ireland Biobank

Governance



- Biobanks need to consider their governance framework
- This includes organisational structure, committees and documentation to enable proper functioning of the biobank
- A good biobank governance framework should help the biobank be transparent, accountable, efficient and fair
- Critical to good governance is engagement with public at all stages of biobank set up and running

Human Tissue Act (2004)



- The Human Tissue Act (2004) regulates the removal, storage, use and disposal of Relevant Material
- Any establishment in England, Wales and Northern Ireland removing and storing human tissue samples for research must have a Human Tissue Authority (HTA) licence, unless an exemption applies. The HTA licence permits the storage of the material.
- The HTA produce Standards they expect licensed establishments to adhere to. The standards fall into four broad categories: Consent; Governance and Quality systems; Traceability; and Premises, Facilities and Equipment.
- The HTA inspect establishments on a cyclical basis to make sure that establishments are meeting these standards.

Ethical considerations



- HRA approval is not required for the establishment of a biobank
- However, many organisations will apply on a voluntary basis for ethical approval
- Advantages of ethical approval:
 - Avoids need for individual project based ethical approval
 - Facilitates more timely review and approval of studies
- Conditions for ethical approval:
 - UKCRC Tissue Directory registration
 - Human Tissue Authority (HTA) License

Ethical considerations



- Broad, enduring consent versus dynamic consent?
- Will your biobank consent for the following?
 - Use of samples in animal models
 - Use of samples in commercial/industry studies
 - Use of samples in cell line models
 - Use of samples for Whole Genome Sequencing
- Tiered consent versus 'all or nothing'
- Arrangements for collection of samples and access to samples
- Will you return incidental findings to donors?
- Age and language appropriate material

Data Protection and Privacy



- Biobanks have a duty to protect the confidentiality and privacy of donors
- Donors must be informed about:
 - What data will be accessed
 - Who will have access to personal data
 - How data will be shared
 - How their privacy will be protected



Of course it's anonymous! ... just make sure you lick the envelope, ok?

Data Protection and Privacy



Biobanks need to consider:

- Methods of de-identification
- Training of personnel who
- Implementing data management, limit and trace

GDPR

Material Transfer Agreement



- A material transfer agreement (MTA) is a legally binding document that governs the conditions under which samples and data can be used
- These must be in line with the conditions of the original consent and ethical approval associated with the samples
- MTA should also address any rights to Intellectual Property generated from the use of the samples and data

Timeline of key events

- Formal request from ECMC/NICCTU for tumour banking Feb 2007
- Formation of NI Tumour Bank Working Group July 2007
- HSC R&D form NI Biobanking Advisory Group Jun 2008
- NI Biobanking Advisory Group report published Dec 2008
- CR-UK Centre Grant awarded to CCRCB Apr 2009
- HSC R&D letter of award July 2010
- Friends of Cancer Centre grant July 2010
- Ethical approval granted Mar 2011
- First sample collected Nov 2011





claire.lewis@qub.ac.uk

www.nibiobank.org



@nibiobank #nibiobank